MEDIPOST
MEDIPOST Raises $140M | Regenerative Medicine for Osteoarthritis
MEDIPOST Closes $140M for Stem Cell Therapy
MEDIPOST, a regenerative medicine company, has raised $140 million in late-stage private funding to advance its allogeneic stem cell therapy for knee osteoarthritis treatment.
The round was led by Skylake Equity Partners and Crescendo Equity Partners.
Key Highlights
- Focus on knee osteoarthritis treatment
- Allogeneic stem cell therapy platform
- Korean growth investor backing
Company Overview
MEDIPOST is developing regenerative medicine therapies using allogeneic stem cells, with a lead program targeting knee osteoarthritis to provide patients with alternatives to joint replacement surgery.
Company Info
Investors (2)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free